


Cheikhou Camara, Laurent Keller and Françoise Dumas\*

Tetrahedron: Asymmetry 14 (2003) 3263





Methyl (R)-3-(1-benzyloxy-2-oxocyclohexyl)-propionate

E.e.=96% (by chiral HPLC)

 $[\alpha]_D^{20}=+32$  (*c* 10, EtOH<sub>abs</sub>)Source of chirality: asymmetric Michael addition using (*R*)-1-phenylethylamine (99% ee)Absolute configuration: (*R*)Claudia Sanfilippo,\* Giovanni Nicolosi, Giovanna Delogu,\*  
Davide Fabbri and Maria Antonietta Dettori

Tetrahedron: Asymmetry 14 (2003) 3267

(a*R*)-(+)-2-Hydroxy-2'-acetoxy-6,6'-dimethoxy-1,1'-biphenyl


E.e.=98% (HPLC)

 $[\alpha]_D^{25}=+91.2$  (*c* 0.7, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: (a*R*)Takamichi Yamagishi,\* Masatoshi Ohnuki, Takahiro Kiyooka,  
Dai Masui, Kiyoshi Sato and Motowo Yamaguchi


Tetrahedron: Asymmetry 14 (2003) 3275

(4*S*,4'*S*)-Bis[2-(4-methyl-4,5-dihydrooxazol-2-yl)phenyl]phenylphosphine

Ee &gt;99%

 $[\alpha]_D^{25}=-56.7$  (*c* 1.27, CH<sub>2</sub>Cl<sub>2</sub>)Source of chirality: (*S*)-alanineAbsolute configuration: 4*S*,4'*S*Takamichi Yamagishi,\* Masatoshi Ohnuki, Takahiro Kiyooka,  
Dai Masui, Kiyoshi Sato and Motowo Yamaguchi

Tetrahedron: Asymmetry 14 (2003) 3275


(4*S*,4'*S*)-Bis[2-(4-isopropyl-4,5-dihydrooxazol-2-yl)phenyl]phenylphosphine

Ee &gt;99%

 $[\alpha]_D^{25}=-50.9$  (*c* 1.66, CH<sub>2</sub>Cl<sub>2</sub>)Source of chirality: (*S*)-valineAbsolute configuration: 4*S*,4'*S*

Takamichi Yamagishi,\* Masatoshi Ohnuki, Takahiro Kiyooka,  
Dai Masui, Kiyoshi Sato and Motowo Yamaguchi

*Tetrahedron: Asymmetry* 14 (2003) 3275



(4*S*,4'*S*)-Bis[2-(4-*t*-butyl-4,5-dihydrooxazol-2-yl)phenyl]phenylphosphine

Ee >99%


$[\alpha]_D^{25} = -39.5$  (*c* 1.97, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (*S*)-*t*-leucine

Absolute configuration: 4*S*,4' *S*

Craig A. Ogle\* and Jason B. Human

*Tetrahedron: Asymmetry* 14 (2003) 3281



C11H17NOS  
(*S*)-2-Methoxymethyl-1-thiophen-3-ylmethyl-pyrrolidine


$[\alpha]_D^{25} = -90$  (*c* 2.0, EtOH)

Source of chirality: L-proline

Absolute configuration: (*S*)

Craig A. Ogle\* and Jason B. Human

*Tetrahedron: Asymmetry* 14 (2003) 3281



C16H21NOS  
(1*S*,2*R*)-Dimethyl-[1-methyl-2-phenyl-2-(thiophen-3-ylmethoxy)-ethyl]amine


$[\alpha]_D^{25} = -50$  (*c* 2.0, EtOH)

Source of chirality: (-)-ephedrine hydrochloride

Absolute configuration: (1*S*,2*R*)

Craig A. Ogle\* and Jason B. Human

*Tetrahedron: Asymmetry* 14 (2003) 3281



C16H21NOS  
(1*S*,2*S*)-Dimethyl-[1-methyl-2-phenyl-2-(thiophen-3-ylmethoxy)-ethyl]amine


$[\alpha]_D^{25} = +74$  (*c* 2.0, EtOH)

Source of chirality: (+)-pseudoephedrine

Absolute configuration: (1*S*,2*S*)

Thomas Prisinzano, Ling-Wei Hsin, John E. Folk,  
Judith L. Flippin-Anderson, Clifford George, Arthur E. Jacobson  
and Kenner C. Rice\*

*Tetrahedron: Asymmetry* 14 (2003) 3285



(*S*)-(+)-1-(4-{2-[Bis-(4-fluorophenyl)methoxy]-ethyl}piperazin-1-yl)-2-phenylpropan-2-ol dimaleate


$[\alpha]_D = +10.4$  (*c* 0.68, MeOH)

Source of chirality: (*S*)-(+)-atrolactic acid

Absolute configuration: *S*

Antonio L. Braga,\* Rodrigo M. Rubim, Henri S. Schrekker,  
Ludger A. Wessjohann, Martin W. G. de Bolster, Gilson Zeni  
and Jasquer A. Sehnem

*Tetrahedron: Asymmetry* 14 (2003) 3291



$\text{C}_{14}\text{H}_{19}\text{NO}_2$


(*S*)-4-(1'-Ethyl-1'-hydroxypropyl)-2-phenyl-1,3-oxazoline

$[\alpha]_D^{20} = +41$  (*c* 0.55,  $\text{CH}_2\text{Cl}_2$ )

Absolute configuration: *S*

Antonio L. Braga,\* Rodrigo M. Rubim, Henri S. Schrekker,  
Ludger A. Wessjohann, Martin W. G. de Bolster, Gilson Zeni  
and Jasquer A. Sehnem

*Tetrahedron: Asymmetry* 14 (2003) 3291



$\text{C}_{22}\text{H}_{19}\text{NO}_2$


(*S*)-4-(Hydroxydiphenylmethyl)-2-phenyl-1,3-oxazoline

$[\alpha]_D^{20} = -41$  (*c* 0.79,  $\text{CH}_2\text{Cl}_2$ )

Absolute configuration: *S*

Zhang Guangyou, Liao Yuqing, Wang Zhaohui, Hiroyuki Nohira  
and Takuji Hirose\*

*Tetrahedron: Asymmetry* 14 (2003) 3297




Dehydroabietic acid 7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid

$[\alpha]_D^{20} = +62.5$  (*c* 2.0, 95% ethanol)

Source of chirality: natural source

Absolute configuration: (1*S*,4*a**S*)




C<sub>9</sub>H<sub>13</sub>NO<sub>2</sub>  
(S)-(+)-1-Amino-3-phenyloxy-2-propanol

[ $\alpha$ ]<sub>D</sub><sup>29</sup> = +2.4 (*c* 1.0, methanol)

Source of chirality: resolution

Absolute configuration: (S)




C<sub>6</sub>H<sub>13</sub>NO  
(1S,2S)-(+)-2-Aminocyclohexanol

[ $\alpha$ ]<sub>D</sub><sup>24</sup> = +8.2 (*c* 1.0, methanol)

Source of chirality: resolution

Absolute configuration: (1S,2S)




C<sub>10</sub>H<sub>14</sub>O<sub>6</sub>  
(R,R)-Diallyl tartrate

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +18.4 (*c* 1.0, MeOH)

Source of chirality: L-tartaric acid

Absolute configuration: (2R,3R)




C<sub>10</sub>H<sub>14</sub>O<sub>6</sub>  
(S,S)-Diallyl tartrate

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -18.9 (*c* 1.0, MeOH)

Source of chirality: D-tartaric acid


Absolute configuration: (2S,3S)

 $C_8H_{12}O_7S$ 

(S,S)-Diethyl-1,3,2-dioxathiolane-2-oxo-4,5-dicarboxylate

 $[\alpha]_D^{20} = +186.5$  (*c* 2.28, MeOH)


Source of chirality: D-tartaric acid

Absolute configuration: (2*S*,3*S*) $C_{18}H_{16}O_7S$ 

(S,S)-Dibenzyl-1,3,2-dioxathiolane-2-oxo-4,5-dicarboxylate

 $[\alpha]_D^{20} = +71.8$  (*c* 1.16, MeOH)


Source of chirality: D-tartaric acid

Absolute configuration: (2*S*,3*S*) $C_{10}H_{12}O_7S$ 

(R,R)-Diallyl-1,3,2-dioxathiolane-2-oxo-4,5-dicarboxylate

 $[\alpha]_D^{20} = -173.5$  (*c* 1.07, MeOH)

Source of chirality: L-tartaric acid


Absolute configuration: (2*R*,3*R*) $C_{10}H_{12}O_7S$ 

(S,S)-Diallyl-1,3,2-dioxathiolane-2-oxo-4,5-dicarboxylate

 $[\alpha]_D^{20} = +167.0$  (*c* 1.12, MeOH)

Source of chirality: D-tartaric acid

Absolute configuration: (2*S*,3*S*)




$C_{18}H_{16}O_8S$   
(*S,S*)-Dibenzyl-1,3,2-dioxathiolane-2,2-dioxo-4,5-dicarboxylate

$[\alpha]_D^{20} = +161.9$  (*c* 1.02, MeOH)

Source of chirality: D-tartaric acid

Absolute configuration: (2*S*,3*S*)




$C_{18}H_{17}N_3O_5$   
(2*S*,3*R*)-Dibenzyl-3-azido-2-hydroxy succinate

$[\alpha]_D^{20} = -37.1$  (*c* 1.1, MeOH)

Source of chirality: D-tartaric acid

Absolute configuration: (2*S*,3*R*)




$C_{10}H_{13}N_3O_5$   
(2*R*,3*S*)-Diallyl-3-azido-2-hydroxy succinate

$[\alpha]_D^{20} = +30.4$  (*c* 2.005, MeOH)

Source of chirality: L-tartaric acid

Absolute configuration: (2*R*,3*S*)




$C_{10}H_{13}N_3O_5$   
(2*S*,3*R*)-Diallyl-3-azido-2-hydroxy succinate

$[\alpha]_D^{20} = -30.7$  (*c* 1.06, MeOH)

Source of chirality: D-tartaric acid

Absolute configuration: (2*S*,3*R*)




$C_{18}H_{17}NO_4$   
(*S,S*)-Dibenzyl aziridine-2,3-dicarboxylate

$[\alpha]_D^{20} = +79.3$  (*c* 1.02, MeOH)

Source of chirality: L-tartaric acid

Absolute configuration: (2*S*,3*S*)




$C_{18}H_{17}NO_4$   
(*R,R*)-Dibenzyl aziridine-2,3-dicarboxylate

$[\alpha]_D^{20} = -79.8$  (*c* 1.04, MeOH)

Source of chirality: D-tartaric acid

Absolute configuration: (2*R*,3*R*)




$C_{10}H_{13}NO_4$   
(*S,S*)-Diallyl aziridine-2,3-dicarboxylate

$[\alpha]_D^{20} = +131.5$  (*c* 1.16, MeOH)

Source of chirality: L-tartaric acid

Absolute configuration: (2*S*,3*S*)




$C_{10}H_{13}NO_4$   
(*R,R*)-Diallyl aziridine-2,3-dicarboxylate


$[\alpha]_D^{20} = -130.8$  (*c* 1.02, MeOH)

Source of chirality: D-tartaric acid


Absolute configuration: (2*R*,3*R*)

 $C_{13}H_{21}NO_6$ (S,S)-1-*tert*-Butyl-2,3-diethyl aziridine-1,2,3-tricarboxylate $[\alpha]_D^{20} = +14.8$  (*c* 1.37, EtOH)

Source of chirality: L-tartaric acid

Absolute configuration: (2*S*,3*S*) $C_{14}H_{21}NO_6$ (S,S)-2-Allyl-1-*tert*-butyl-3-ethyl aziridine-1,2,3-tricarboxylate $[\alpha]_D^{20} = +9.0$  (*c* 1.06, MeOH)


Source of chirality: L-tartaric acid

Absolute configuration: (2*S*,3*S*) $C_{10}H_{20}O$ (1*R*,3*R*,4*S*)-(-)-Menthol

Ee = 97% (by GC analysis of its acetate)

 $[\alpha]_D^{20} = -48.9$  (*c* 2, EtOH)

Source of chirality: lipase PS resolution

Absolute configuration: 1*R*,3*R*,4*S* $C_{12}H_{22}O_2$ (1*R*,3*R*,4*S*)-(-)-Menthol acetate

Ee = 97% (by GC analysis)


 $[\alpha]_D^{20} = -80.5$  (*c* 2, CHCl<sub>3</sub>)

Source of chirality: lipase PS resolution

Absolute configuration: 1*R*,3*R*,4*S*

Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313




C<sub>10</sub>H<sub>18</sub>O  
(1*R*,3*R*,4*S*)-(-)-Isopulegol

Ee=98% (by GC analysis of its acetate)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-13.6 (c 1, CHCl<sub>3</sub>)  
Source of chirality: lipase PS resolution  
Absolute configuration: 1*R*,3*R*,4*S*

Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313




C<sub>12</sub>H<sub>20</sub>O<sub>2</sub>  
(1*R*,3*R*,4*S*)-(-)-Isopulegol acetate

Ee=98% (by GC analysis)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-17.9 (c 1, CHCl<sub>3</sub>)  
Source of chirality: lipase PS resolution  
Absolute configuration: 1*R*,3*R*,4*S*

Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313




C<sub>10</sub>H<sub>18</sub>O  
(3*S*,4*S*)-(-)-trans-Piperitol

Ee=99% (by GC analysis of its acetate)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-30.4 (c 2, EtOH)  
Source of chirality: lipase PS resolution  
Absolute configuration: 3*S*,4*S*

Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313




C<sub>12</sub>H<sub>20</sub>O<sub>2</sub>  
(3*S*,4*S*)-(-)-trans-Piperitol acetate

Ee=99% (by GC analysis of its acetate)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-144.6 (c 2, CHCl<sub>3</sub>)  
Source of chirality: lipase PS resolution  
Absolute configuration: 3*S*,4*S*

Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313




C<sub>10</sub>H<sub>18</sub>O  
(3S,4R)-(-)-*cis*-Piperitol

Ee=99% (by GC analysis of its acetate)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-203 (c 2, EtOH)  
Source of chirality: lipase PS resolution  
Absolute configuration: 3*S*,4*R*

Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313




C<sub>12</sub>H<sub>20</sub>O<sub>2</sub>  
(3S,4R)-(-)-*cis*-piperitol acetate

Ee=99% (by GC analysis)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-376 (c 2, CHCl<sub>3</sub>)  
Source of chirality: lipase PS resolution  
Absolute configuration: 3*S*,4*R*

Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313




C<sub>10</sub>H<sub>16</sub>O  
(3R,4R)-(-)-*cis*-Isopiperitenol

Ee=99% (by GC analysis of its acetate)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-228 (c 2, EtOH)  
Source of chirality: lipase PS resolution  
Absolute configuration: 3*R*,4*R*


Stefano Serra,\* Elisabetta Brenna, Claudio Fuganti  
and Francesco Maggioni

Tetrahedron: Asymmetry 14 (2003) 3313



C<sub>12</sub>H<sub>18</sub>O<sub>2</sub>  
(3R,4R)-(-)-*cis*-Isopiperitenol acetate

Ee=99% (by GC analysis)  
[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-378 (c 2, CHCl<sub>3</sub>)  
Source of chirality: lipase PS resolution  
Absolute configuration: 3*R*,4*R*




C<sub>10</sub>H<sub>14</sub>O  
(4S)-(+)-Isopiperitenone

Ee = 70%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +30.1 (c 2, CHCl<sub>3</sub>)

Source of chirality: lipase PS resolution

Absolute configuration: 4S



C<sub>28</sub>H<sub>25</sub>FeNO<sub>3</sub>S  
Methyl (2S,3R)-1-[(S<sub>Fc</sub>)-(p-tolylsulfanyl)ferrocenoyl]-3-phenyl-aziridine-2-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>20</sup> -32.6 (c 0.59, CHCl<sub>3</sub>)

D.e. >99

E.e. >99

Source of chirality: asymmetric synthesis and  
chemical resolution

Absolute configuration: (2R,3S,S<sub>Fc</sub>)



C<sub>21</sub>H<sub>19</sub>FeNO<sub>3</sub>  
Methyl (2S,3R)-1-ferrocenoyl-3-phenyl-aziridine-2-carboxylate


[ $\alpha$ ]<sub>D</sub><sup>20</sup> -33.2 (c 0.48, CHCl<sub>3</sub>)

D.e. >99

E.e. >99

Source of chirality: chemical resolution

Absolute configuration: (2R,3S)



C<sub>32</sub>H<sub>29</sub>FeN<sub>2</sub>O<sub>6</sub>  
1,1'-Bis[(2S,3R)keto(3-phenyl-2-methoxycarbonyl)-aziridin-1-yl]ferrocene

[ $\alpha$ ]<sub>D</sub><sup>20</sup> +115.2 (c 0.73, CHCl<sub>3</sub>)

D.e. >99



E.e. >99

Source of chirality: chemical resolution

Absolute configuration: (2R,3S)

Bianca F. Bonini,\* Mariafrancesca Fochi, Mauro Comes-Franchini, Alfredo Ricci, Lambertus Thijs and Binne Zwanenburg\*

*Tetrahedron: Asymmetry* 14 (2003) 3321



Methyl (5R,4S)-2-[{(S<sub>Fc</sub>)}-(*p*-tolylsulfanyl)ferrocenyl]-5-phenyl-oxazoline-4-carboxylate

[ $\alpha$ ]<sub>D</sub><sup>20</sup> +230 (*c* 0.815, CHCl<sub>3</sub>)

D.e. >99


E.e. >99

Source of chirality: asymmetric synthesis and chemical resolution

Absolute configuration: (5*R*,4*S*,*S<sub>Fc</sub>*)

Bianca F. Bonini,\* Mariafrancesca Fochi, Mauro Comes-Franchini, Alfredo Ricci, Lambertus Thijs and Binne Zwanenburg\*

*Tetrahedron: Asymmetry* 14 (2003) 3321



Methyl (5*R*,4*S*)-2-ferrocenyl-5-phenyl-oxazoline-4-carboxylate

[ $\alpha$ ]<sub>D</sub><sup>20</sup> +51.5 (*c* 0.71, CHCl<sub>3</sub>)

D.e. >99


E.e. >99

Source of chirality: chemical resolution

Absolute configuration: (5*R*,4*S*)

Bianca F. Bonini,\* Mariafrancesca Fochi, Mauro Comes-Franchini, Alfredo Ricci, Lambertus Thijs and Binne Zwanenburg\*

*Tetrahedron: Asymmetry* 14 (2003) 3321



1,1'-Bis[(5*R*,4*S*)-5-phenyl-4-methoxycarbonyl-oxazolin-2-yl]ferrocene

[ $\alpha$ ]<sub>D</sub><sup>20</sup> +128.3 (*c* 0.5, CHCl<sub>3</sub>)

D.e. >99



E.e. >99

Source of chirality: chemical resolution

Absolute configuration: (5*R*,4*S*)

Bianca F. Bonini,\* Mariafrancesca Fochi, Mauro Comes-Franchini, Alfredo Ricci, Lambertus Thijs and Binne Zwanenburg\*

*Tetrahedron: Asymmetry* 14 (2003) 3321



(5*R*,4*S*)-2-[{(S<sub>Fc</sub>)}-(*p*-Tolylsulfanyl)ferrocenyl]-5-phenyl-4-(1-hydroxy-1-methylethyl) oxazoline


[ $\alpha$ ]<sub>D</sub><sup>20</sup> +98.0 (*c* 0.585, CHCl<sub>3</sub>)

D.e. >99

E.e. >99

Source of chirality: asymmetric synthesis and chemical resolution

Absolute configuration: (5*R*,4*S*,*S<sub>Fc</sub>*)



C<sub>22</sub>H<sub>23</sub>FeNO<sub>2</sub>  
(5R,4S)-2-Ferrocenyl-5-phenyl-4-(1-hydroxy-1-methylethyl)oxazoline


[ $\alpha$ ]<sub>D</sub><sup>20</sup> -31.6 (*c* 0.98, CHCl<sub>3</sub>)

D.e. >99

E.e. >99

Source of chirality: chemical resolution

Absolute configuration: (5R,4S)



C<sub>34</sub>H<sub>36</sub>FeN<sub>2</sub>O<sub>4</sub>  
1,1'-Bis[(4S,5R)-5-phenyl-4-(1-hydroxy-1-methylethyl)oxazolin-2-yl]-ferrocene


[ $\alpha$ ]<sub>D</sub><sup>20</sup> -67 (*c* 0.43, CHCl<sub>3</sub>)

D.e. >99

E.e. >99

Source of chirality: chemical resolution


Absolute configuration: (4S,5R)



C<sub>33</sub>H<sub>34</sub>O<sub>10</sub>NP  
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-{[2-(diphenylphosphino)benzoyl]amino}-β-D-glucopyranose

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +36.3 (*c* 1, CHCl<sub>3</sub>)


Source of chirality: 2-amino-1,3,4,6-tetra-*O*-acetyl-2-deoxy-β-D-glucopyranose




C<sub>25</sub>H<sub>26</sub>O<sub>6</sub>NP  
2-Deoxy-2-{[2-(diphenylphosphino)benzoyl]amino}-D-glucopyranose

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +25.2 (*c* 1, THF)


Source of chirality: 2-amino-2-deoxy-D-glucopyranose

 $C_{23}H_{23}N_2$ *N*-[(6*S*)-6,11-Dihydro-5*H*-dibenzo[*b,e*]azepin-6-ylmethyl]-*N*-(1'*S*-1-phenylethyl)amine $[\alpha]_D^{22} = +40.5$  (*c* 1.2, CHCl<sub>3</sub>)


Source of chirality: diastereoselective synthesis

Absolute configuration: (6*S*)-(1'*S*) $C_{23}H_{23}N_2$ *N*-[(6*R*)-6,11-Dihydro-5*H*-dibenzo[*b,e*]azepin-6-ylmethyl]-*N*-(1'*S*-1-phenylethyl)amine $[\alpha]_D^{22} = -89$  (*c* 1.2, CHCl<sub>3</sub>)

Source of chirality: diastereoselective synthesis


Absolute configuration: (6*R*)-(1'*S*) $C_{25}H_{22}N_2O_2$ (14b*R*)-2-(1'*S*-1-Phenylethyl)-1,2,10,14b-tetrahydrodibenzo[*c,f*]pyrazino[1,2-*a*]azepine-3,4-dione $[\alpha]_D^{22} = -156$  (*c* 1.2, CHCl<sub>3</sub>)

Source of chirality: diastereoselective synthesis

Absolute configuration: (14b*R*)-(1'*S*) $C_{25}H_{22}N_2O_2$ (14b*S*)-2-(1'*S*-1-Phenylethyl)-1,2,10,14b-tetrahydrodibenzo[*c,f*]pyrazino[1,2-*a*]azepine-3,4-dione $[\alpha]_D^{22} = +85$  (*c* 1.2, CHCl<sub>3</sub>)

Source of chirality: diastereoselective synthesis


Absolute configuration: (14b*S*)-(1'*S*)

 $C_{25}H_{26}N_2$ 


(14bR)-2-(1'S-1-Phenylethyl)-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine

 $[\alpha]_D^{22} = -341.8$  (*c* 1.1, CHCl<sub>3</sub>)

Source of chirality: diastereoselective synthesis

Absolute configuration: (14b*R*)-(1'*S*) $C_{25}H_{26}N_2$ (14b*S*)-2-(1'S-1-Phenylethyl)-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine $[\alpha]_D^{22} = +157.7$  (*c* 0.91, CHCl<sub>3</sub>)

Source of chirality: diastereoselective synthesis

Absolute configuration: (14b*S*)-(1'*S*)


E.e. &gt;99%


 $[\alpha]_D^{20} = -403$  (*c*=0.036, chloroform)

Source of chirality: resolution

Absolute configuration : *R* $C_{13}H_{16}FeOP_2$ 

(R)-3,3',4,4'-Tetramethyl-1,1'-diphosphaferrrocene-2-carboxaldehyde

 $C_{32}H_{37}FeNO_2Si$ 1-[(*S*)-4-Isopropyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenyltrimethylsilyloxymethyl)ferrocene $[\alpha]_D^{20} = -82.6$  (*c* 0.16, CHCl<sub>3</sub>)Source of chirality: (*S*)-valinolAbsolute configuration: (*S*)




C<sub>33</sub>H<sub>39</sub>FeNO<sub>2</sub>Si  
1-[(S)-4-tert-Butyl-2,5-oxazolinyl]-1'-(α-diphenyltrimethylsiloxyethyl)ferrocene

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -116 (c 0.28, CHCl<sub>3</sub>)

Source of chirality: (S)-*tert*-leucinol

Absolute configuration: (S)




C<sub>36</sub>H<sub>37</sub>FeNO<sub>2</sub>Si  
1-[(S)-4-Benzyl-2,5-oxazolinyl]-1'-(α-diphenyltrimethylsiloxyethyl)ferrocene

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -14 (c 0.15, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylaniol

Absolute configuration: (S)




C<sub>35</sub>H<sub>35</sub>FeNO<sub>2</sub>Si  
1-[(R)-4-Phenyl-2,5-oxazolinyl]-1'-(α-diphenyltrimethylsiloxyethyl)ferrocene

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +97.2 (c 0.35, CHCl<sub>3</sub>)

Source of chirality: (R)-phenylglycinol

Absolute configuration: (R)




C<sub>30</sub>H<sub>31</sub>FeNO<sub>2</sub>  
1-[(S)-4-Isopropyl-2,5-oxazolinyl]-1'-(α-diphenylhydroxymethyl)-2-(R<sub>p</sub>)-methylferrocene

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -281 (c 0.24, CHCl<sub>3</sub>)

Source of chirality: (S)-valinol

Absolute configuration: (S,R<sub>p</sub>)




$C_{31}H_{33}FeNO_2$   
1-[(S)-4-tert-Butyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenylhydroxymethyl)-2-(Rp)-methylferrocene

$[\alpha]_D^{20} = -358$  ( $c$  0.27, CHCl<sub>3</sub>)

Source of chirality: (S)-*tert*-leucinol

Absolute configuration: (S,Rp)




$C_{34}H_{31}FeNO_2$   
1-[(S)-4-Benzyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenylhydroxymethyl)-2-(Rp)-methylferrocene

$[\alpha]_D^{20} = -224$  ( $c$  0.10, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylaniol

Absolute configuration: (S,Rp)




$C_{33}H_{29}FeNO_2$   
1-[(R)-4-Phenyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenylhydroxymethyl)-2-(Sp)-methylferrocene

$[\alpha]_D^{20} = +284$  ( $c$  0.10, CHCl<sub>3</sub>)

Source of chirality: (R)-phenylglycinol

Absolute configuration: (R,Sp)





$C_{35}H_{45}FeNO_2Si_2$   
1-[(S)-4-Isopropyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenyltrimethylsilyloxymethyl)-2-(Sp)-trimethylsilylferrocene

$[\alpha]_D^{20} = +49$  ( $c$  0.195, CHCl<sub>3</sub>)

Source of chirality: (S)-valinol

Absolute configuration: (S,Sp)





1-[(S)-4-tert-Butyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenyltrimethylsiloxyethyl)-2-(Sp)-trimethylsilylferrocene

$[\alpha]_D^{20} = +129$  ( $c$  0.09,  $CHCl_3$ )

Source of chirality: (*S*)-*tert*-leucinol

Absolute configuration: (*S,Sp*)




1-[(S)-4-Isopropyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenylhydroxymethyl)-2-(Sp)-methylferrocene

$[\alpha]_D^{20} = +136$  ( $c$  0.23,  $CHCl_3$ )

Source of chirality: (*S*)-valinol

Absolute configuration: (*S,Sp*)




1-[(S)-4-tert-Butyl-2,5-oxazolinyl]-1'-( $\alpha$ -diphenylhydroxymethyl)-2-(Sp)-methylferrocene

$[\alpha]_D^{20} = +127$  ( $c$  0.15,  $CHCl_3$ )

Source of chirality: (*S*)-*tert*-leucinol

Absolute configuration: (*S,Sp*)




E.e. >98%

$[\alpha]_D = +36.9$  ( $c$  1.0,  $H_2O$ )

Source of chirality: (*S*)-phenylethylamine

Absolute configuration: 3*R*,4*R*




C<sub>15</sub>H<sub>27</sub>NO<sub>4</sub>  
Methyl (3*R*,4*R*)-1-*t*-butoxycarbonyl-4-(2'-methylprop-1'-yl)-3-pyrrolidine carboxylate

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = +37.5 (*c* 2.0, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 3*R*,4*R*




C<sub>14</sub>H<sub>27</sub>NO<sub>3</sub>  
(3*R*,4*R*)-1-(*t*-Butoxycarbonyl)-3-hydroxymethyl-4-(2'-methylprop-1'-yl)pyrrolidine

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = +35.8 (*c* 4.6, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 3*R*,4*R*




C<sub>24</sub>H<sub>33</sub>NO  
(3*R*,4*R*,1'S)-4-Benzylloxymethyl-3-(2''-methylprop-1''-yl)-1-(1'-phenylethyl)pyrrolidine

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = +10.1 (*c* 1, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 3*R*,4*R*,1'S




C<sub>21</sub>H<sub>33</sub>NO<sub>3</sub>  
(3*R*,4*R*)-1-(*t*-Butoxycarbonyl)-3-hydroxymethyl-4-(2'-methylprop-1'-yl)pyrrolidine

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = +26.8 (*c* 0.5, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 3*R*,4*R*




C<sub>20</sub>H<sub>23</sub>NO<sub>2</sub>  
(4S,1'S)-4-Benzylloxymethyl-1-(1'-phenylethyl)pyrrolidin-2-one

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = -79.4 (c 1, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 4S,1'S




C<sub>24</sub>H<sub>31</sub>NO<sub>2</sub>  
(3S,4S,1'S)-4-Benzylloxymethyl-3-(2''-methylprop-1''-yl)-1-(1'-phenylethyl)pyrrolidin-2-one

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = -75.2 (c 1, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 3S,4S,1'S




C<sub>24</sub>H<sub>33</sub>NO  
(3S,4S,1'S)-4-Benzylloxymethyl-3-(2''-methylprop-1''-yl)-1-(1'-phenylethyl)pyrrolidine

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = -38.6 (c 0.7, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 3S,4S,1'S




C<sub>20</sub>H<sub>23</sub>NO<sub>2</sub>  
(4R,1'S)-4-Benzylloxymethyl-1-(1'-phenylethyl)pyrrolidin-2-one

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = -38.4 (c 1, CHCl<sub>3</sub>)

Source of chirality: (S)-phenylethylamine

Absolute configuration: 4R,1'S




C<sub>24</sub>H<sub>31</sub>NO<sub>2</sub>  
(3*R*,4*R*,1'*S*)-4-Benzylloxymethyl-3-(2''-methylprop-1''-yl)-1-(1'-phenylethyl)pyrrolidin-2-one

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = -56.1 (*c* 1, CHCl<sub>3</sub>)

Source of chirality: (*S*)-phenylethylamine

Absolute configuration: 3*R*,4*R*,1'*S*




C<sub>9</sub>H<sub>17</sub>NO<sub>2</sub>  
(3*R*,4*R*)-4-(2'-Methylprop-1'-yl)-3-pyrrolidine carboxylic acid

E.e. >98%

[ $\alpha$ ]<sub>D</sub> = +43.8 (*c* 0.5, MeOH)

Source of chirality: (*S*)-phenylethylamine

Absolute configuration: 3*R*,4*R*




Diethyl (*S*)-3-[(*tert*-butoxycarbonyl)amino]-2-hydroxypropylphosphonate

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -2.6 (*c* 2.8 in CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*)




(*S*)-3-Amino-2-hydroxypropylphosphonic acid

E.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -41.4 (*c* 0.9 in H<sub>2</sub>O)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*)




C<sub>27</sub>H<sub>21</sub>NO<sub>5</sub>

Benzoic acid 2-[2-oxo-(5R)-5-[(1S)-3-oxo-1,3-dihydroisobenzofuran-1-yl]-2,5-dihydropyrrolidin-1-yl]-(2R)-2-phenylethyl ester

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +175 (c 0.5, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis and separation

Absolute configuration: (5R,1'S,2''R) (chemical correlation)




C<sub>27</sub>H<sub>23</sub>NO<sub>5</sub>

Benzoic acid 2-[2-oxo-(5R)-5-[(1S)-3-oxo-1,3-dihydroisobenzofuran-1-yl]pyrrolidin-1-yl]-(2R)-2-phenylethyl ester

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +56 (c 0.7, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis and separation

Absolute configuration: (5R,1'S,2''R) (chemical correlation)




C<sub>27</sub>H<sub>25</sub>NO<sub>4</sub>

Benzoic acid 2-[(2R)-2-[(1S)-3-oxo-1,3-dihydroisobenzofuran-1-yl]pyrrolidin-1-yl]-(2R)-2-phenylethyl ester

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +34 (c 1.6, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis and separation

Absolute configuration: (2R,1'S,2''R) (X-ray crystallography)




C<sub>12</sub>H<sub>13</sub>NO<sub>2</sub>

10-Hydroxy-(10S,10aR)-2,3,10,10a-tetrahydro-1H-pyrrolo[1,2-b]isoquinolin-5-one

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -172 (c 0.5, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis and separation

Absolute configuration: (2R,3S) (chemical correlation)




C<sub>17</sub>H<sub>21</sub>NO<sub>4</sub>

(2*R*)-2-[(1*S*)-3-Oxo-1,3-dihydroisobenzofuran-1-yl]pyrrolodone-1-carboxylic acid *tert*-butyl ester

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +51 (*c* 0.7, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis and separation

Absolute configuration: (2*R*,1*S*) (chemical correlation)




C<sub>12</sub>H<sub>15</sub>NO

(2*R*)-2-[(1*S*)-1,3-Dihydroisobenzofuran-1-yl]pyrrolidine

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +24 (*c* 0.45, CH<sub>3</sub>OH)

Source of chirality: asymmetric synthesis and separation

Absolute configuration: (2*R*,1*S*) (chemical correlation)



C<sub>12</sub>H<sub>20</sub>O<sub>4</sub>


(3*S*,4*R*)-3-Acetoxy-2,2,4-trimethyl-hex-5-enoic acid methyl ester

E.e. = 85%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +8.5 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*)



C<sub>10</sub>H<sub>18</sub>O<sub>3</sub>


(3*S*,4*R*)-3-Hydroxy-2,2,4-trimethyl-hex-5-enoic acid methyl ester

E.e. = 85%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +12.2 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*)



C<sub>9</sub>H<sub>16</sub>O<sub>4</sub>


(3S,4S)-3-Hydroxy-2,2,4-trimethyl-5-oxo-pentanoic acid methyl ester

E.e. = 85%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +13.8 (c 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S,4S)



C<sub>9</sub>H<sub>14</sub>O<sub>3</sub>


(3S,4S)-3-Acetoxy-2,2,4-trimethyl-5-oxo-pentanoic acid methyl ester

E.e. = 85%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +13.1 (c 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S,4S)



C<sub>14</sub>H<sub>24</sub>O<sub>4</sub>


(3S,4R)-3-Hydroxy-2,2,4-trimethyl-7-oxo-dec-5-enoic acid methyl ester

E.e. = 85%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +12.1 (c 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S,4R)



C<sub>16</sub>H<sub>26</sub>O<sub>5</sub>


(3S,4R)-3-Acetoxy-2,2,4-trimethyl-7-oxo-dec-5-enoic acid methyl ester

E.e. = 85%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +30.6 (c 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3S,4R)




$C_{16}H_{28}O_5$   
(3*S*,4*R*,7*S*)-3-Acetoxy-7-hydroxy-2,2,4-trimethyl-dec-5-enoic acid methyl ester

E.e. = 85%

$[\alpha]_D^{25} = +24.2$  (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*,7*S*)




$C_{16}H_{28}O_5$   
(3*S*,4*R*,7*R*)-3-Acetoxy-7-hydroxy-2,2,4-trimethyl-dec-5-enoic acid methyl ester

E.e. = 85%

$[\alpha]_D^{25} = -1.8$  (*c* 0.6, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*,7*R*)




$C_{16}H_{30}O_5$   
(3*S*,4*R*,7*S*)-3-Acetoxy-7-hydroxy-2,2,4-trimethyl-decanoic acid methyl ester

E.e. = 85%

$[\alpha]_D^{25} = +17.2$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*,7*S*)




$C_{17}H_{32}O_5$   
(3*S*,4*R*,7*S*)-3-Acetoxy-7-methoxy-2,2,4-trimethyl-decanoic acid methyl ester

E.e. = 85%

$[\alpha]_D^{25} = +12.9$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*,7*S*)




$C_{14}H_{28}O_4$   
(3*S*,4*R*,7*S*)-3-Hydroxy-7-methoxy-2,2,4-trimethyl-decanoic acid

E.e. = 85%

$[\alpha]_D^{25} = -31.8$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (3*S*,4*R*,7*S*)




$C_{11}H_{13}O_5P$   
Carboxymethyl(methoxycarbonylmethyl)phenylphosphine oxide

E.e. = 72%

$[\alpha]_D^{20} = +3.9$  (*c* 1.1, MeOH)

Source of chirality: enzymatic asymmetric synthesis

Absolute configuration: *R*, chemical correlation




$C_{10}H_{13}O_4P$   
Acetoxymethyl(hydroxymethyl)phenylphosphine oxide

E.e. = 48%

$[\alpha]_D^{20} = -2.4$  (*c* 1.34, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis

Absolute configuration: *S*, chemical correlation




$C_{17}H_{19}O_6PS$   
Acetoxymethyl(tosyloxymethyl)phenylphosphine oxide

E.e. = 48%

$[\alpha]_D^{20} = -14.55$  (*c* 1.12, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis

Absolute configuration: *R*, chemical correlation




Hydroxymethyl(methyl)phenylphosphine oxide

E.e. = 48%

$[\alpha]_D^{20} = +9.4$  (*c* 1.01, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis

Absolute configuration: *R*, chemical correlation




Acetoxy(iodomethyl)phenylphosphine oxide

E.e. = 48%

$[\alpha]_D^{20} = -10.1$  (*c* 1.39, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis

Absolute configuration: *R*, chemical correlation




Methyl(trimethylsilyloxymethyl)phenylphosphine oxide

E.e. = 48%

$[\alpha]_D^{20} = -5.2$  (*c* 1.10, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis

Absolute configuration: *R*, chemical correlation




Hydroxymethyl(methyl)phenylphosphine P-borane

E.e. = 7%

$[\alpha]_D^{20} = -0.5$  (*c* 1.57, CHCl<sub>3</sub>)

Source of chirality: stereoselective synthesis

Absolute configuration: *R*, chemical correlation




C<sub>12</sub>H<sub>15</sub>NO<sub>2</sub>S  
4-(2-Hydroxy-(1*R*)-phenylethyl)-thiomorpholin-3-one

Ee = 100%

[ $\alpha$ ]<sub>D</sub><sup>18</sup> = -102 (*c* 1, EtOH)

Source of chirality: asymmetric synthesis

Absolute configuration: (1*R*)




C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub>S  
(2*R*)-Methyl-4-(2-hydroxy-(1'*R*)-phenylethyl)thiomorpholin-3-one

Ee >96%

[ $\alpha$ ]<sub>D</sub><sup>18</sup> = -97 (*c* 0.1, EtOH)

Source of chirality: alkylation of 4-(2-hydroxy-(1*R*)-phenylethyl)-thiomorpholin-3-one

Absolute configuration: (1'*R*,2*R*)




C<sub>19</sub>H<sub>21</sub>NO<sub>2</sub>S  
(2*R*)-Benzyl-4-(2-hydroxy-(1'*R*)-phenylethyl)thiomorpholin-3-one

Ee >99%

[ $\alpha$ ]<sub>D</sub><sup>18</sup> = -99 (*c* 0.1, EtOH)

Source of chirality: alkylation of 4-(2-hydroxy-(1*R*)-phenylethyl)-thiomorpholin-3-one

Absolute configuration: (1'*R*,2*R*)




C<sub>15</sub>H<sub>19</sub>NO<sub>2</sub>S  
(2*R*)-Allyl-4-(2-hydroxy-(1'*R*)-phenylethyl)thiomorpholin-3-one

Ee >96%

[ $\alpha$ ]<sub>D</sub><sup>18</sup> = -97 (*c* 0.1, EtOH)

Source of chirality: alkylation of 4-(2-hydroxy-(1*R*)-phenylethyl)-thiomorpholin-3-one

Absolute configuration: (1'*R*,2*R*)



C<sub>11</sub>H<sub>13</sub>NOS


(2R)-Benzylthiomorpholin-3-one

E.e.=99%

[ $\alpha$ ]<sub>D</sub><sup>18</sup>=+33.9 (*c* 0.05, EtOH)

Source of chirality: *N*-debenzylation of (2*R*)-benzyl-4-(2-hydroxy-(1'R)-phenylethyl)thiomorpholin-3-one

Absolute configuration: (2*R*)



C<sub>18</sub>H<sub>23</sub>N<sub>2</sub>PS


(1*R*,2*R*)-(-)-*N*-Diphenylthiophosphoryl-cyclohexane-1,2-diamine

E.e.=100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-22.8 (*c* 0.072, CHCl<sub>3</sub>)

Source of chirality: resolution

Absolute configuration: (1*R*,2*R*)



C<sub>20</sub>H<sub>27</sub>N<sub>2</sub>PS


(1*R*,2*R*)-(-)-*N*-Ethyl-*N*'-diphenylthiophosphoryl-cyclohexane-1,2-diamine

E.e.=100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-53.5 (*c* 0.095, CHCl<sub>3</sub>)

Source of chirality: resolution

Absolute configuration: (1*R*,2*R*)



C<sub>20</sub>H<sub>27</sub>N<sub>2</sub>PS


(1*R*,2*R*)-(-)-*N,N*-Dimethyl-*N*'-diphenylthiophosphoryl-cyclohexane-1,2-diamine

E.e.=100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup>=-31.1 (*c* 2.2, CHCl<sub>3</sub>)

Source of chirality: resolution


Absolute configuration: (1*R*,2*R*)

 $C_{28}H_{29}N_2PS$ (1*R*,2*R*)(*-*)-*N*-Ethyl-*N'*-diphenylthiophosphoryl-1,2-diphenylethane-1,2-diamine

E.e. = 100%

 $[\alpha]_D^{20} = -7.1$  (*c* 1.55, CHCl<sub>3</sub>)


Source of chirality: resolution

Absolute configuration: (1*R*,2*R*) $C_{10}H_{23}N_2PS$ (1*R*,2*R*)(*-*)-*N*-Ethyl-*N'*-Dimethylthiophosphoryl-cyclohexane-1,2-dimine


E.e. = 100%

 $[\alpha]_D^{20} = -138.4$  (*c* 0.6, CHCl<sub>3</sub>)

Source of chirality: resolution


Absolute configuration: (1*R*,2*R*) $C_{16}H_{19}NO_2S$ 4-Methyl-*N*-(1-phenyl-propyl)-benzenesulfonamide

E.e. = 68%


 $[\alpha]_D^{20} = -35.6$  (*c* 3.17, CHCl<sub>3</sub>)Absolute configuration: (*S*) $C_{33}H_{32}FeNOP$ (R)-*N*-[1-(3-Methoxyphenyl)ethylidene]-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. =&gt;98%


 $[\alpha]_D^{25} = -351$  (*c* 0.10, CHCl<sub>3</sub>)Source of chirality: (*R*)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamineAbsolute configuration: central chirality: *R*, planar chirality: *S*

 $C_{32}H_{29}ClFeNP$ *(R)*-*N*-[1-(3-Chlorophenyl)ethylidene]-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine


E.e. = &gt;98%

 $[\alpha]_D^{25} = -366$  (*c* 0.13, CHCl<sub>3</sub>)Source of chirality: (*R*)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamineAbsolute configuration: central chirality: *R*, planar chirality: *S* $C_{32}H_{29}FeN_2O_2P$ *(R)*-*N*-[1-(3-Nitrophenyl)ethylidene]-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. = &gt;98%


 $[\alpha]_D^{25} = -381$  (*c* 0.13, CHCl<sub>3</sub>)Source of chirality: (*R*)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamineAbsolute configuration: central chirality: *R*, planar chirality: *S* $C_{33}H_{29}F_3FeNP$ *(R)*-*N*-[1-(3-Trifluoromethylphenyl)ethylidene]-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. = &gt;98%

 $[\alpha]_D^{25} = -348$  (*c* 0.11, CHCl<sub>3</sub>)Source of chirality: (*R*)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamineAbsolute configuration: central chirality: *R*, planar chirality: *S* $C_{33}H_{31}FeN_2O_2P$ *(R)*-*N*-[1-(3-Nitrophenyl)ethylidene]-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]propylamine

E.e. = &gt;98%

 $[\alpha]_D^{25} = -369$  (*c* 0.11, CHCl<sub>3</sub>)Source of chirality: (*R*)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]propylamineAbsolute configuration: central chirality: *R*, planar chirality: *S*



C<sub>32</sub>H<sub>29</sub>FeN<sub>2</sub>O<sub>2</sub>P

(S)-N-[1-((3-Nitrophenyl)ethylidene]-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e.=>98%

[ $\alpha$ ]<sub>D</sub><sup>25</sup>=-31.2 (*c* 0.076, CHCl<sub>3</sub>)

Source of chirality: (S)-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: *S*, planar chirality: *S*